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Abstract 
The synthesis of imidazole styrylbenzamides, tert-butyl styrylimidazole and tert-butyl 
styrylsufonate derivatives is described. Evaluation of binding affinity and inhibitory 
activity against CYP24A1 identified the imidazole styrylbenzamides (8) as potent 
inhibitors of CYP24A1, and selectivity with respect to CYP27B1, comparable with or 
greater than the standard ketoconazole. Further evaluation of the 3,5-dimethoxy 
derivative (8d) and 3,4,5-trimethoxy derivative (8e) in chronic lymphocytic leukaemia 
(CLL) cells revealed that co-treatment of 1,25-dihydroxyvitamin D3 plus inhibitor
coordinately upregulated GADD45 and CDKN1A. Docking experiments of the 
inhibitors in the CYP24A1 enzyme active site would suggest the compounds reach the 
active site through the vitamin D access tunnel and are exposed to multiple hydrophobic 
residues. The imidazole styrylbenzamides (8) are optimally positioned to allow 
interaction of the imidazole with the haem and, in the case of the methoxy derivatives, a 
hydrogen bond between the 3-methoxy group and Gln82 stabilises the molecule in a 
favourable active conformation. 
Key words: (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-4-styrylbenzamides; vitamin D 
receptor; CYP24A1; anti-proliferative activity; molecular modeling 
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INTRODUCTION 
The active form of vitamin D3, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, 
calcitriol) (Figure 1), has a multifaceted role in human physiology including regulation of 
calcium and phosphate homeostasis and mobilisation of bone mineral,1 immunology 
through its influence on cytokine production,2 cell proliferation and regulation of gene 
transcription.3 Reduction of circulating calcitriol is associated with several diseases such 
as cancers,4-6 autoimmune dysfunction7,8 and chronic kidney disease.9,10 This reduction in 
circulating calcitriol is concomitant with upregulation or overexpression of the 
cytochrome P450 enzyme 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) responsible 
for the inactivation, through metabolic hydroxylation, of calcitriol and 25-
hydroxyvitamin D3 (25(OH)D3).11 
Inhibition of CYP24A1 is therefore an attractive strategy to overcome the 
inhibitory effects of CYP24 on VDR regulated gene expression. Two main classes of 
CYP24A1 inhibitors have been described, calcitriol/vitamin D derivatives and azole 
inhibitors. Both classes have their challenges; calcitriol therapy is limited by 
hypercalcaemia and this side-effect can be associated with vitamin D derivatives, 
whereas for the azole inhibitors the challenge is selectivity for CYP24A1 over the other 
major vitamin D3 metabolising enzyme CYP27B1. Success in developing vitamin D 
derivatives with reduced hypercalcaemic effects have been reported12,13 and includes the 
sulfone CTA0189,12 and sulfoximine CTA091,9,13 sulfonate TS17,14 imidazole VIMI and 
cyclopropylamine CPA115 (Figure 1). 
 
4 
 
 
Figure 1. Reported vitamin D-like CYP24A1 inhibitors 
 
Although the standard used for comparison in all the CYP24A1 inhibitor 
publications is the azole ketoconazole (Figure 2), there are fewer published reports for the 
azole CYP24A1 inhibitors. Ketoconazole, a broad spectrum CYP inhibitor is an azole 
compound with CYP24A1 inhibitory activity and approximately 4-fold selectivity for 
CYP24A1 vs CYP27B1 reported.16 Schuster et al.17 described the azole compound (R)-
VID400 (Figure 2), which displayed a 40-fold selectivity for CYP24A1 over CYP27B1. 
The non-selective CYP inhibitor liarozole (Figure 2) has been shown to prolong the half-
life of calcitriol and enhance up-regulation of vitamin D receptor (VDR) in DU 145 
prostate cancer cell line.18  
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Figure 2. Azole CYP24A1 inhibitors and target compounds 
 
This manuscript describes SAR studies on the potent imidazole styrylbenzamides 
previously described by us,19 tert-butyl styrylimidazole and tert-butyl styrylsufonate 
derivatives (Figure 2), with CYP24A1 selectivity vs CYP27B1 and antiproliferative data 
for the most potent inhibitors. The substitution of the phenyl ring of the imidazole 
styrylbenzamides was investigated; in addition the effect of maintaining the C25 tert-
butyl terminal of calcitriol in the styrylbenzamides with inclusion of either an imidazole 
(c.f. VIMI, Figure 1) or sulfonate (c.f. TS17, Figure 1) haem-binding motif was explored. 
 
RESULTS 
Chemistry. The styrenes (2) were prepared by Wittig reaction of the 
corresponding aldehyde (1) with methyltriphenylphosphonium bromide and potassium 
tert-butoxide following described methodology.20 Heck reaction of the styrenes (2) with 
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4-bromobenzoic acid (3) produced the 4-[(E)-2-phenyl-1-ethylenyl]benzoic acids (4).19,21-
23
 The synthesis of the (E)-4-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)styrylbenzamides 
(6) was carried out using 1,1’-carbonyldiimidazole (CDI) with 2-amino-1-phenyl-ethanol 
(5) (Scheme 1).  
The 4,5-dihydro-1,3-oxazoles (7) were prepared by the reaction of the 
styrylbenzamides (6) with methanesulphonyl chloride and a triethylamine at room 
temperature for 24 h.19,24,25 In the last step of the reaction scheme, heating the oxazole 
compound (7) in the presence of imidazole opened the oxazole ring by nucleophilic 
displacement (Scheme 1).19,26 A good yield of compound (8a-8e) was produced after 
purification by column chromatography. Catalytic hydrogenation of compound 8b, using 
Pd/C 10% wt under H2 atmosphere in THF, gave the reduced derivative 8f (Scheme 1). 
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Scheme 1. Reagents and Conditions: (i) PhCH3Br, tBuOK, 3 h (ii) 4-bromobenzoic acid 
(3), Pd(OAc)2, ToP, Et3N, 100 oC, 20 h (iii) 2-amino-1-phenyl-ethanol (5), CDI, 20 h (iv) 
CH3SO2Cl, Et3N, 24 h (v) imidazole, isopropyl acetate, 125 °C, 48 h (vi) Pd/C 10% wt, 
H2 atmosphere, THF, 72 h. 
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4-(N-Phenyl)-sulfamoyl benzoic acid (9), prepared using a reported method27 for 
the sulphonamide preparation reacting aniline and 4-(chlorosulfonyl) benzoic acid in 
pyridine at 0 °C and then overnight at room temperature, was reacted with 1-amino-2-
phenyl ethanol (5) to form the amidic bond, following the method previously quoted, 
producing the phenylsulfamoyl-benzamide derivative (10). The 4,5-dihydro-1,3-oxazole 
(11) was prepared from compound 10 as reported above, and the excess of 
methanesulphonyl chloride mesylated the nitrogen of the sulphonamide bond. 
Introduction of the imidazole ring in the lateral chain was achieved by reaction of the 
oxazole (11) in isopropylacetate in the presence of excess imidazole. An excess of 
imidazole was added in order to act as base and remove the mesyl protection of the 
nitrogen, obtaining compound (12) (Scheme 2). 
 
 
Scheme 2. Reagents and Conditions: (i) 2-amino-1-phenyl-ethanol (5), CDI, 20 h (ii) 
CH3SO2Cl, Et3N, 24 h (iii) imidazole, isopropyl acetate, 125 °C, 48 h. 
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Heck reaction of the styrenes (2) with 1-(4-bromophenyl)-4,4-dimethylpentan-3-
one (15), prepared by the reaction of 1-bromo-4-(bromomethyl)benzene (13) and 1-(tert-
butylvinyloxy)trimethylsilane (14) catalyzed by indium (III) bromide following 
methodology described by Nishimoto et al.,28 produced the ketones (16a and 16b), which 
were subsequently reduced to the corresponding alcohols (17a and 17b) on reaction with 
sodium borohydride (Scheme 3). Attempts to prepare the imidazole derivative (19b) by 
reaction of the alcohol (17b) using imidazole/ CDI, following our previously described 
methodology, led to isolation of the intermediate carbonyl imidazole (18b) only. An 
alternative method to introduce the imidazole ring was to first convert the alcohols (17a 
and 17b) to a good leaving group, which could then be displaced by the imidazole anion. 
To this end the alcohols (17a and 17b) were converted to the mesylates (20a and 20b) on 
reaction with methanesulfonly chloride in CH2Cl2 and dimethylaminopyridine (DMAP). 
Attempts to then displace the mesylate with the imidazole anion, generated on reaction of 
imidazole with sodium hydride in DMF, were unsuccessful with no reaction observed 
(Scheme 3).  The failure of both imidazole reactions was likely owing to both steric 
hindrance from the bulky tert-butyl group and electronic factors reducing the reactivity of 
the CH-OH towards nucleophilic substitution.  
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Scheme 3. Reagents and Conditions: (i) InBr3, CH2Cl2, 2 h (ii) Pd(OAc)2, ToP, Et3N, 110 
oC, 6 h (iii) NaBH4, EtOH, 2 h (iv) imidazole, CDI, CH3CN, 70 °C, 48 h (v) CH3SO2Cl, 
DMAP, CH2Cl2,  24 h (vi) NaH, imidazole, DMF, 45 oC, 24 h (vii) 4-toluenesulfonyl 
chloride, DMAP, CH2Cl2,  reflux, 24 h. [a R1 = R2 = R3 = H; b R1 = R3 = OCH3, R2 = H] 
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The sulfonates (20a and 20b) were however of interest as potential inhibitors and 
in addition a tosylate derivative (21b) was also prepared for biological evaluation, 
however, unlike the mesylates, the tosylate (21b) was obtained in very low yield even 
after extensive heating with mainly starting material recovered. The failure of the tosylate 
reaction to reach completion could again be owing to steric hindrance by the lateral tert-
butyl group reducing nucleophilic attack by the more bulky tosyl group compared with 
the smaller mesyl group. 
 
Scheme 4. Reagents and Conditions: (i) K2CO3, Ac2O, 3 h (ii) Pd/C 10% wt, H2 
atmosphere, THF, 72 h 
 
Minor changes in the tert-butyl styrylimidazole derivatives involved moving the 
imidazole ring from the third lateral carbon to the second and introducing a double bond 
in the lateral chain to introduce rigidity to the structure (Scheme 4). The lateral 
imidazole-tert-butyl chain (22) was easily prepared reacting imidazole, sodium hydride 
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and 1-bromopinacolone in DMF following the method reported by Todory et al.29 The 4-
styryl-benzaldehyde (23) was obtained via Heck reaction of styrene with 4-
bromobenzaldehyde. Aldol condensation between 22 and 23 using K2CO3 as base in 
acetic anhydride gave the desired (E/Z)-2-imidazol-1-yl-4,4-dimethyl-1-(4-styryl-
phenyl)-pent-1-en-3-one (24) as mixture of E/Z isomers. Catalytic hydrogenation of 24 
produced the 2-imidazol-1-yl-4,4-dimethyl-1-(4-phenylethyl)-pentan-3-one (23) (Scheme 
4). 
CYP24A1 enzyme inhibition. The CYP24A1 enzymatic assay followed 
methodology previously described,14 in short human CYP24A1 with an N-terminal 
fusion to maltose binding protein (MBP) was overexpressed in Escherichia coli and 
purified to homogeneity. The hydrolase activity was reconstituted in vitro, and the 
resulting cell-free assay system applied in the screening of the compounds to measure Ki 
and IC50 (Table 1). 
The imidazole styrylbenzamide derivatives 8 were the most active with optimal 
activity observed for the 3,5-dimethoxy and 3,4,5-trimethoxy substitution (8d, Ki 7.8 nM, 
IC50 0.11 M; 8e, Ki 9.7 nM, IC50 0.14 M). Reduction of the styrene double bond 
resulted in a decreased activity (8f, Ki 36 nM, IC50 0.51 M) and replacing the double 
bond with a sulphonamide group resulted in a more notable reduction in activity (12, Ki 
91 nM, IC50 1.3 M). Replacing the imidazole with sulphonates (20 and 21) resulted in a 
substantial loss in activity, likewise the keto tert-butyl derivative 16 also displayed poor 
inhibitory activity compared with the standard ketoconazole (Ki 33 nM, IC50 0.47 M). 
Interestingly the intermediate carbonyl imidazole derivative 18b showed inhibitory 
activity (18b, Ki 11 nM, IC50 0.16 M) comparable with the imidazole styrylbenzamide 
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derivatives 8. Moving the position of the imidazole group from position three to position 
2 of the lateral chain resulted in good inhibitory activity for the styryl derivative (24, Ki 
13 nM, IC50 0.18 M) however when the alkene bonds were reduced introducing 
flexibility inhibitory activity was decreased (25, Ki 42 nM, IC50 0.6 M).  
 
Table 1. IC50 and Ki data vs CYP24A1 and CYP27B1 
Compound CYP24A1 CYP27B1 Selectivity 
 IC50 ;μMͿ KI ;μMͿ 
 
IC50 ;μMͿ 
 
KI ;μMͿ 
KI 
(CYP27B1/C
YP24A1) 
8a 0.40 0.028 ± 0.006 0.50 0.080 ± 0.005 2.8 
8b 0.26 0.019 ± 0.003 0.60 0.097 ± 0.015 5.1 
8c 0.34 0.024 ± 0.003 0.24 0.040 ± 0.009 1.7 
8d 0.11 0.0078 ± 0.0008 0.16 0.026 ± 0.002 3.3 
8e 0.14 0.0097 ± 0.0012 0.33 0.053 ± 0.006 5.5 
8f 0.51 0.036 ± 0.004 0.28 0.045 ± 0.004 1.2 
12 1.3 0.091 ± 0.021    
16b 2.1 0.15 ± 0.04  0.13 0.89 
18b 0.16 0.011 ± 0.002 0.20 0.033 ± 0.006 3.0 
20a 5.6 0.40 ± 0.02    
20b 5.4 0.38 ± 0.07  0.13 0.34 
21b 2.9 0.21 ± 0.04    
24 0.18 0.013 ± 0.001 0.036 0.0057 ± 0.0004 0.44 
25 0.60 0.042 ± 0.003 0.23 0.037 ± 0.004 0.88 
Ketoconazole 0.47 0.033  0.36 0.058 1.7 
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CYP27B1 enzyme inhibition. Inhibition assay of CYP27B1 was performed in a similar 
way to the CYP24A1 assay as previously described,14 and the resulting cell-free assay 
system applied in the screening of the compounds to measure Ki and IC50 (Table 1). 
Compounds with good binding and inhibitory activity against CYP24A1 also displayed 
similar properties against CYP27B1. Selectivity similar or greater than the standard, 
ketoconazole (selectivity CYP27B1/CYP24A1 = 1.7) was observed for most of the 
compounds, most notably the styryl imidazoles 8b and 8e had 5-fold selectivity for 
CYP24A1 over CYP27B1. 
Compounds 8d and 8e were subject to further evaluation to determine effect on CLL cells 
and vitamin D receptor (VDR) genes. 
 
Effects of 1,25-(OH)2D3 and CYP24A1 inhibitors on CLL cells. The imidazole 
styrylbenzamides 8 were analysed for anti-cancer activity in primary CLL cells. Primary 
CLL cells were more sensitive to the effects of calcitriol when compared with normal B-
cells with a mean LD50 of 0.28M (Figure 3a). The differential toxicity in CLL cells 
versus normal B-cells can be explained by the enhanced CYP24A1 expression in CLL 
cells.30 This selectivity was also observed for compound 8d and to a much lesser extent 
for compound 8e (Figure 3b, Table 2).  
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Figure 3. Apoptotic effects of calcitriol and CYP24A1 inhibitors in CLL and normal 
B-cells. 
(a) Primary CLL cells and normal B-cells were purified by negative selection using CD3+ 
Dyanbeads. Cells were then cultured for 48h in the presence of calcitriol (0-10M) and 
apoptosis was assessed using Annexin V/propidium iodide labelling and quantified by 
flow cytometry. CLL cells were >20 times more sensitive to the effects of calcitriol when 
compared with normal B-cells. (b) Primary CLL cells were treated with the CYP24A1 
16 
 
inhibitors 8d and 8e for 24h. Furthermore, 8d was selectively toxic to CLL cells when 
compared to normal B-cells following incubation with CYP24A1 inhibitor for 48h. 
The in vitro cytotoxicity of the novel CYP24 inhibitors was evaluated in primary CLL 
cells (n = 6) (Table 2).  Experiments were performed in duplicate and the LD50 values 
expressed as mean (SD) for the six samples tested. Sensitivity to fludarabine (a 
commonly used treatment for CLL) was assessed in the same primary leukemia cells; the 
data indicate that a number of the CYP24 inhibitors were more potent than fludarabine. 
The data obtained (Table 2) clearly show a detrimental effect of a 4-methoxy substituent 
(8c and 8e IC50 3.4 M) on anti-cancer activity compared with the unsubstituted, 4-fluoro 
and 3,5-dimethoxy derivatives (8a IC50 27 nM, 8b IC50 15 nM and 8d IC50 13 nM 
respectively).  
 
Table 2. The in vitro cytotoxicity of the novel CYP24 inhibitors was evaluated in primary 
CLL cells (n = 6)   
Compound R1 R2 R3 LD50 (M) 
8a H H H 0.027 (± 0.018) 
8b H F H 0.015 (± 0.011) 
8c H OCH3 H 3.2 (± 0.14) 
8d OCH3 H OCH3 0.013 (± 0.01) 
8e OCH3 OCH3 OCH3 3.5 (± 0.15) 
Fludarabine    1.1 (± 0.32) 
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Effects of 1,25-(OH)2D3 and CYP24A1 inhibitors on CLL cells. The results here 
showed that treatment with 10 nM 1,25-(OH)2D3 had no significant effect on GADD45 
and CDKN1A mRNA expression in CLL cells compared with untreated cells (Figure 4). 
At 100 nM 1,25-(OH)2D3 a small enhancement was observed. However, when the cells 
were treated with 8d in combination with 100 nM calcitriol the GADD45 mRNA was 
enhanced significantly (P < 0.01) and induction was dependent on inhibitor concentration 
with optimal enhancement observed at 0.05-0.10 M CYP24A1 inhibitor 8d in 
combination with 100 nM calcitriol (Figure 4A). Induction of CDKN1A mRNA on 
combination with 100 nM calcitriol/0.01-0.10 M 8d was also significant (P < 0.05) 
(Figure 4B). Combination of 1,25-(OH)2D3  (100 nM) with 8e (0.05-0.10 M) resulted in 
a significant (P < 0.05) induction of GADD45 and CDKN1A mRNA expression (Figure 
4C and 4D).  
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Figure 4. CYP24A1 inhibition significantly increases the transcription of vitamin D 
target genes in a dose-dependent manner. 
Primary CLL cells were treated with 8d in the presence and absence of 10nM and 100nM 
calcitriol for 24h. The transcription of GADD45A, CDKN1A and RPS14 (house-keeping 
gene) were analysed by quantitative RT-PCR on a LightCycler 2.0 instrument. Relative 
changes in transcription were expressed as the ratio of target gene to RPS14. 8d caused a 
dose-dependent increase in relative transcription of (A) GADD45A and (B) CDKN1A. 
This was further enhanced in the presence of calcitriol. In contrast, 8e did not induce 
19 
 
significant changes in (C) GADD45A or (D) CDKN1A unless co-administered with 
100nM calcitriol. *, P<0.05; **, P<0.001. 
 
Molecular Modeling.  
Homology Model 
Homology model of the human CYP24A1 was built with MOE-homology tool using a 
single template approach following the methodology previously reported by our group 
and using the Amber99 force field.31 The crystal structure of the rat enzyme isoform (pdb 
ID:3K9V)32 was used as template, considering the high sequence similarity (83%) with 
the human one as reported in literature.15 The sequence of the human isoform was loaded 
in MOE together with the 3D structure of the rat isoform, aligned and the final 3D model 
was obtained as single output structure. Validation of the new model in terms of the 
stereochemical quality of the backbone, side chain and amino acids environment were 
conducted using the on-line applications RAMPAGE server, Verify 3D and Errat.33,34,35 
 
DISCUSSION 
The (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-4-styrylbenzamides (8) were readily 
prepared using an efficient 5-step synthesis. The results of the CYP24A1 inhibition assay 
would suggest substitutions on the styryl phenyl ring are important to activity. The 
unsubstituted compound (8a) had low activity, whereas the introduction of substituents 
on the ring resulted in an improvement in activity up to 4-fold. Introduction of methoxy 
groups in positions 3 and 5 (R1 and R3) (8d) and in 3,4,5 position (8e) led to the best 
activity with a Ki in the nM range. Substitution in the 4-position (R2, Table 1) with F or 
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OCH3 in compounds 8b and 8c was detrimental to activity. Hydrogenation of the styryl 
linker produces a decrease in activity (8f), which was more evident after its replacement 
with a sulphonamide (12). Although any SAR for this small series is very preliminary, 
molecular docking studies can provide a rational explanation for the observed enzymatic 
data. All the compounds reached the active site through the vitamin D access tunnel and 
were exposed to multiple hydrophobic residues (Ile131, Trp134, Met246, Phe249, 
Thr394, Thr395, Gly499, Tyr500), which have been reported having multiple 
hydrophobic interactions with calcitriol.32,35 This pose allows the imidazole ring in an 
optimal position for the interaction between its nitrogen lone pair and the haem iron. 
Compounds 8d and 8e present an additional hydrogen bond between their 3-methoxy 
group and Gln82, which stabilises the two compounds in the favourable active 
conformation and could explain the small improvement in CYP24A1 inhibition activity 
(Figure 5).  
 
Figure 5: Docking of 8d: the compound occupies the access tunnel with the imidazole 
ring in an optimal orientation for the interaction with the iron. The hydrogen bond 
between its 3-methoxy group and Gln82 stabilises the molecule in a favourable active 
conformation. 
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The rest of the compound family, lacking this extra hydrogen bond, is free to move in the 
wide pocket and consequently their binding poses in the active site are more variable with 
reduced activity observed (Figure 6).   
 
Figure 6: Docking of 8a: Due to the absence of hydrogen bond with Gln82, the molecule 
binding poses in the active site are more variable, possibly justifying the reduced activity 
observed for this compound. 
 
The molecule flexibility conferred by hydrogenation of styryl linker (8f) or by its 
replacement by sulphonamide (12) results in a reduction in activity in the first case and a 
decrease of activity in the second emphasizing the importance of the structural rigidity in 
the active site disposition. The docking has shown how, due to the high flexibility of the 
sulphonamide bond, compound 12 assumes multiple possible conformations in the 
binding pocket and none of them allow the correct disposition in the active site (Figure 
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7).  
 
 
Figure 7: Docking of 12: Due to the high flexibility of the sulphonamide bond, 
compound 12 is not able to entirely occupy the access channel. 
 
To further validate the binding mode of the docking results, 5 ns molecular dynamics 
(MD) studies were performed for compounds 8a-d and 12 considering the protein 
flexibility and the interaction changes of ligand-protein complex during the time. The 
hydrophobic nature of the active site is an optimal environment for these lipophilic 
molecules and this could be an explanation for the stability shown by most of the 
different systems. Furthermore, a haem-imidazole coordination is present during all the 
simulation for all the derivatives, except for compound 12, with an optimal distance Fe-N 
for the interaction between 2.40 and 3.85 Å (Table 3).  
 
 
23 
 
Table 3. Calculated ligand interaction energies for the compounds analysed by molecular 
dynamics. 
Compound ΔGbinding (Kj/mol)* Fe-N distance (Å)* 
8d -19.83183 2.58 
8b -17.26674 2.40 
8c -14.52405 3.85 
8a -13.95545 2.74 
12 3.49442 5.48 
 
*Average values of ΔGbinding and Fe-N distance calculated excluding the first 2ns of MD 
in which the system protein-ligand reached stability. 
 
The lowest estimate ΔGbinding energy was found for compound 8d, whereas compound 12 
showed the highest energy value. This relation between the estimate ΔGbinding and the 
enzymatic assay results was also found for compound 8a, 8b and 8c (Table 3). The best 
results for compound 8d could be a consequence of the hydrogen bond with Gln82 
(Graphic 1), which keeps the molecule in the right conformation for all the MD duration 
giving a further contribution to the system stability. 
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Graphic 1: Trend, during the 5ns MD simulation, of the distance O-N in the hydrogen 
bond formation between the 3-methoxy group of 8d and Gln82. After 2ns of stabilization, 
the average distance is 3.51 Å. 
 
 The high value of energy reported for compound 12 is a consequence of the high 
flexibility of the sulphonamide bond. The molecule is not able to accommodate entirely 
in the enzyme access channel during all 5ns MD simulation. As consequence of that, 
compound 12 loses its imidazole-iron coordination and therefore part of its anti-
CYP24A1 inhibitory activity. Graphic 2 reports the Fe-N distance trend during the 5ns 
MD of compound 8d and 12. After the system stabilization in the first 2ns, the distance 
remains stable for 8d, while the distance increment for compound 12 indicates a loss of 
coordination to the haem. 
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Graphic 2: Distance Fe-N trend during 5ns MD simulation. After 2ns of stabilization, the 
distance remains stable for 8d, while the distance increment for compound 12 indicates a 
loss of coordination to the haem. 
 
None of the sulfonate/tosylate derivatives (20a, 20b, 21b) showed interesting CYP24A1 
activity underlining the key rule of the imidazole ring in the binding to the haem, and a 
further confirmation was given by the activity found for compound 18b, 24 and 25, in 
which the imidazole was present in the lateral chain. The nitrogen lone pair could be 
more available for the interaction with the iron if compared with the oxygen one making 
the sulfonate-Fe interaction weaker than imidazole-Fe resulting in an ineffective anti-
CYP24A1 activity. 
Further biological evaluation of two of the CYP24A1 inhibitors, (E)-N-(2-(1H-imidazol-
1-yl)-2-phenylethyl)-4-(3,5-dimethoxystyryl)benzamide (8d) and (E)-N-(2-(1H-imidazol-
1-yl)-2-phenylethyl)-4-(3,4,5-trimethoxystyryl)benzamide (8e) were conducted to 
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determine the effect of the inhibitors of VDR target genes GADD45 and CDKN1A. 
Induced expression of GADD45 inhibits cell proliferation and is induced by various 
agents that damage DNA and arrest cell growth.36 CDKN1A (also known as p21waf1), a 
cell-cycle regulatory protein inhibits the activity of cyclin-dependent kinases in the G0/G1 
cell-cycle phase, resulting in cell-cycle arrest. Induction of GADD45 and CDKN1A has 
been shown to contributes to the growth-inhibitory effects of 1,25-(OH)2D3.37  
Co-administration of the dimethoxy derivative (8d) with 100 nM 1, 25-(OH)2D3 
significantly enhanced the induction of GADD45 (P < 0.01) and CDKN1A (P < 0.05) 
(Figure 4 A/B) with optimal induction observed with a concentration of 0.05-0.10 M of 
inhibitor 8d. Co-administration of the trimethoxy derivative (8e) with 100 nM 1, 25-
(OH)2D3 significantly enhanced the induction of GADD45 and CDKN1A (P < 0.05) 
(Figure 4 C/D) with optimal induction observed with a concentration of 0.05-0.10 M of 
inhibitor 8e. The effect on induction of both VDR target genes was significant however 
the effects were more marked for the combination of 8d/1,25-(OH)2D3 compared with 
8e/1,25-(OH)2D3. 
 
Conclusions 
Optimal binding and inhibitory activity was achieved with the imidazole derivatives (8, 
18 and 24) and with a rigid styryl moiety. Docking and molecular dynamics experiments 
provide a rationale for the importance of conformational stability to allow the inhibitor to 
entirely occupy the access channel and coordinate with the haem. The 3-methoxy group 
in compounds 8d and 8e presents an additional hydrogen bond between their 3-methoxy 
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group and Gln82, which stabilises the two compounds in the favourable active 
conformation with an improvement in CYP24A1 inhibitory activity.  
Modest CYP24A1 vs CYP27B1 selectivity was achieved with the imidazole 
styrylbenzamides (8) with > 5-fold selectivity observed for the 4-fluoro and 3,4,5-
trimethoxy derivatives, 8b and 8d, respectively, which was an improvement compared 
with the 1.7-fold selectivity observed for ketoconazole (Table 1). The nanomolar 
inhibitory activity and modest selectivity of the imidazole styrylbenzamides (8) combined 
with the significant induction of VDR target genes GADD45 and CDKN1A in primary 
chronic CLL cells provides useful lead compounds for further development. 
 
EXPERIMENTAL SECTION 
General Procedures. 1,25(OH)2D3 and 25(OH)D3 were purchased from SAFC-
Pharma (Madison, WI). Human MBP-CYP24A1, mouse CYP27B1, bovine adrenodoxin 
(Adx), and adrenodoxin reductase (AdR) were purified as described previously.14 
1H and 13C NMR spectra were recorded with a Brucker Avance DPX500 
spectrometer operating at 500 and 125MHz, with Me4Si as internal standard.Mass 
spectrometry data was acquired at the EPSRC UK National Mass Spectrometry Facility 
at Swansea University. Microanalyses were determined by Medac Ltd (Surrey, UK). 
Flash column chromatography was performed with silica gel 60 (230-400mesh) (Merck) 
and TLC was carried out on precoated silica plates (kiesel gel 60 F254, BDH). Melting 
points were determined on an electrothermal instrument and are uncorrected. Compounds 
were visualised by illumination under UV light (254 nm) or by the use of vanillin stain 
followed by charring on a hotplate. All solvents were dried prior to use as described by 
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the handbook Purification of Laboratory Chemicals38 and stored over 4Å molecular 
sieves, under nitrogen. All compounds were more than 95% pure. 
The benzoic acids (4) were prepared according to literature methods19,20-22 and the 
synthesis of (8a) was previously reported.19 
 CYP24A1 inhibition assay.  
Inhibition of CYP24A1 was carried out as described previously.14 Briefly, reaction 
mixture containing 0.1 μM each of Adx and AdR, 0.075 μM MBP-CYP24A1, 2.5 μM 
1,25(OH)2D3, varying concentrations of inhibitors, and 0.5 mM NADPH was incubated 
at 37 °C for 25 min in a buffer of 20 mM Tris (pH 7.5) and 125 mM NaCl. All inhibitors 
were dissolved in ethanol (>10 mM) or DMSO (>50 mM) and further diluted in ethanol 
to make working stock (<1 mM). The reaction was extracted with CH2Cl2 and analyzed 
by HPLC. The IC50 values were determined by fitting the relative activity (V/V0) against 
the inhibitor concentration [I] using the equation V/V0 = IC50/(IC50 + [I]), where V and V0 
are the reaction rates in the presence and absence of inhibitors. The KI values were 
calculated using equation KI = IC50/(1 + [S]/KM), where [S] is the substrate concentration 
and KM = 0.19 μM.14 
CYP27B1 inhibition assay.  
Inhibition assay of CYP27B1 was performed in a similar way to that of CYP24A1 as 
previously described.14 The concentration of substrate 25(OH)D3 was 2.5 μM and KM for 
CYP27B1 was 0.48 μM. 
Cell culture conditions 
Freshly isolated peripheral blood lymphocytes (1x106/ml) were cultured in RPMI 
medium (Invitrogen) supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, 
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10% fetal calf serum and 5ng/ml IL-4. Both CLL cells and normal B-cells were purified 
by negative selection using CD3+ Dyanbeads (Invitrogen); purity was assessed by flow 
cytometry and only samples with >90% target cells were used in subsequent experiments. 
Lymphocytes were incubated at 37oC in a humidified 5% carbon dioxide atmosphere in 
the presence of CYP24 inhibitors (0 – 1x10-7M) and/or calcitriol (0 - 1x10-5M) for up to 
48h. In addition, control cultures were set up in which no drug was added to normal and 
leukaemic lymphocytes. Cells were subsequently harvested by centrifugation and were 
analyzed by flow cytometry using the methods outlined below. Experiments were 
performed either in duplicate or triplicate. 
Measurement of in vitro apoptosis 
Cells were harvested and then resuspended in the supplied binding buffer according to 
the manufacturer’s instructions (Bender Medsystems). Subsequently, 4μl of fluorescein-
labelled Annexin V was added to each aliquot of cells in then incubated in the dark for 10 
mins. Cells were then washed and resuspended in binding buffer with 10μl propidium 
iodide. Apoptosis was quantified on an Accuri C6 flow cytometer (Becton Dickinson) 
and analysed using CFlow software. LD50 values were calculated from the sigmoidal 
dose-response curves using Prism 6.0 software (Graphpad). All experiments were 
performed in triplicate.  
 
RT-PCR analysis of GADD45A and CDKN1A transcription 
1x107 CLL lymphocytes and normal B-lymphocytes were incubated with 8d and 8e (0, 
0.01, 0.05 and 0.1M) for 24h in the presence or absence of calcitriol (10nM and 
100nM). Cells were harvested and total RNA was extracted from using RNeasy spin 
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columns according to the manufacturer’s instructions (Qiagen, Crawley, UK). One 
microgram of total RNA was then reverse transcribed using a Clontech first strand cDNA 
synthesis kit (Clontech, Between Towns, UK). Subsequently real time PCR was 
performed using gene-specific primers for GADD45A, CDKN1A and ribosomal protein 
RPS14 (house-keeping gene) in PCR buffer containing 50nM of each primer, 4.0 mM 
MgCl2 cDNA template and FastStart SYBR Green I DNA master mix (Roche 
Diagnostics, UK) in a 10 µl final volume. Each reaction was cycled 35 times consisting 
of 10 sec denaturation (95oC), 5 sec annealing (60oC) and 20 sec extension (72oC) on a 
Roche LightCycler 2.0 instrument (Roche Diagnostics). The amount of RPS14 mRNA 
was quantified in all samples as an internal house-keeping control and SYBRGreen was 
used as the detection method. The results of the real-time RT-PCR were expressed as 
normalised target gene values, e.g. the ratio between GADD45A and RPS14 transcripts 
calculated from the crossing points of each gene. All experiments were performed in 
duplicate.  The gene-specific primer pairs used were as follows:  
GADD45A:   
Forward primer sequence: GCAGGATCCTTCCATTGAGA   
Reverse primer sequence: CTCTTGGAGACCGACGCTG   
 
CDKN1A:  
Forward primer sequence: CATGGGTTCTGACGGACAT   
Reverse primer sequence: AGTCAGTTCCTTGTGGAGCC 
 
RPS14 (house-keeping gene): 
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Forward primer sequence: GGCAGACCGAGATGAACTCT  
Reverse primer sequence: CCAGGTCCAGGGGTCTTGGT  
 
  
Molecular Modelling 
Docking studies were performed using LeadIT2.1.2 docking program by BioSolve.IT.39 
The important amino acid residues of the active pocket (Gln82, Ile131, Trp134, Met246, 
Ala326, Glu329, Thr330, Val391, Phe393, Thr394, Ser498, Gly499, Tyr500)32 were 
selected and then the selection was extended to 12 Å in order to include in the docking 
site the haem iron region and the access tunnel to the catalytic site. A ligands database in 
mol2 format, prepared using MOE,40 was used as input for the docking calculations. The 
iron atom of the catalytic site was set as essential pharmacophoric feature. Ligand 
docking was performed using the default values and no water molecules were considered. 
Ten output solutions were obtained from each compound and visual inspection in MOE 
was used to identify the interaction between ligand and protein.  
All molecular dynamics simulations were performed and analysed using the GROMACS 
4.5 simulation package.41 The Amber99 force field was used. Parameters of the ligands 
were built using the ANTECHAMBER tool of Amber tools. The Amber forcefield 
parameters of haem group reported by Akifumi et al. were used.42 The initial structure of 
each ligand, chosen as best result from docking studies, either free in solution or in 
complex with the enzyme, was placed in a cubic box with TIP 3P water and consequently 
energy minimised using a steepest descent minimization algorithm. The system was 
equilibrated via a 100 ps MD simulation at 300K a NVT canonical environment then an 
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additional 100 ps simulation at constant pressure of 1 atm was performed (NPT). After 
the equilibration phases, a 5 ns MD simulation was performed at constant temperature 
(300 K) and pressure with a time step of 2 fs.  Electro-static and Van der Waals ligand-
surrounding energies were stored, from MD simulations of the ligands in complex with 
the enzyme and when free in solution every 3 ps, together with their spatial coordinates, 
for further analysis.  
The estimate ΔGbinding was calculated using GROMACS g_lie function based on LIE 
equation.43,44 The method requires the calculation of average interaction energies between 
the ligand and its surroundings from molecular dynamics (MD) simulations of the ligand 
free in solution and when bound to the enzyme.  
 Chemistry. General Method - Synthesis of Carboxamide Derivatives (6 and 10). To 
a suspension of carboxylic acid (4 or 9) (5 mmol) in anhydrous DMF (5 mL) was added 
1,1’-carbonyldiimidazole (5 mmol) and the reaction stirred at room temperature for 1 h. 
The reaction was cooled to 0 °C and subsequently combined with a solution of 2-amino-
1-phenyl-ethanol (5) (5 mmol) in DMF (5 mL). The mixture was stirred at room 
temperature for 8 h. After the reaction was complete, an aliquot amount of ice was poured 
into the flask to precipitate out the product, which was then filtered, washed with ice-cold 
H20 and dried under vacuum with phosphorus pentoxide.  
 N-(2-Hydroxy-2-phenylethyl)-4-[(E)-2-(4-fluorophenyl)vinyl]benzamide (6b). A 
white solid was obtained. Yield: 83 %, Rf 0.88 (petroleum ether – EtOAc 1:3 v/v); m.p. 
200-202 oC; 1H-NMR (DMSO-d6):  8.53 (t, J = 5.2 Hz, 1H, NH), 7.87 (d, J = 8.2 Hz, 
2H, Ar), 7.76-7.70 (m, 4H, Ar), 7.22-7.40 (m, 9H, Ar and alkene), 5.54 (bs, 1H, OH), 
4.81 (dd, J = 5.8, 7.9 Hz, 1H, CHOH), 3.49-3.53 (m, 1H, NHCH2), 3.31-3.37 (m, 1H, 
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NHCH2). 13 C-NMR (DMSO-d6): 166.0 (C=O), 162.8, 160.9, 143.8, 139.7, 133.4, 
133.4, 133.3 (C, Ar), 130.3, 128.9, 128.6, 128.5, 128.0, 127.7, 127.4, 127.0, 126.1, 126.0, 
115.7, 115.5 (CH, Ar), 71.2 (CH, CH-OH), 47.7 (CH2). Anal. Calcd. for 
C23H20O2FN•0.1H2O (363.22): C, 76.06 %, H, 5.61 %, N, 3.86 %. Found: C, 75.88 %, H, 
5.48 %, N, 3.59 %. 
 N-(2-Hydroxy-2-phenylethyl)-4-[(E)-2-(4-methoxyphenyl)vinyl]benzamide (6c). A 
white solid was obtained. Yield: 74 %, Rf 0.58 (petroleum ether – EtOAc 1:3 v/v); m.p. 
230-232 oC; 1H-NMR (DMSO-d6):  7.86 (t, J = 5.5 Hz, 1H, NH), 7.64 (d, J = 8.2 Hz, 
2H, Ar), 7.58 (d, J = 8.6 Hz, 2H, Ar), 7.24-7.40 (m, 6H, Ar and alkene), 7.13-7.16 (m, 
1H, Ar), 6.97 (d, J = 8.6 Hz, 2H, Ar), 5.54 (bs, 1H, OH), 4.81 (dd, J = 4.8, 8.0 Hz, 1H, 
CHOH), 3.79 (s, 3H, OCH3), 3.32-3.54 (m, 2H, NHCH2). 13 C-NMR (DMSO-d6): 166.1 
(C=O), 159.3, 140.8, 140.1, 132.8, 130.2 (C, Ar), 130.6, 129.8, 129.4, 128.4, 127.0, 
126.0, 125.8, 125.2, 114.2 (CH, Ar), 71.2 (CH, CH-OH), 55.4 (CH3), 47.7 (CH2). Anal. 
Calcd. for C24H23O3N•0.3H2O (378.86): C, 76.09 %, H, 6.28 %, N, 3.70 %. Found: C, 
75.78 %, H, 6.22 %, N, 3.43 %. 
 N-(2-Hydroxy-2-phenylethyl)-4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]benzamide (6d). 
A white solid was obtained. Yield: 75 %, Rf 0.66 (petroleum ether – EtOAc 1:3 v/v); m.p. 
168-170 oC; 1H-NMR (DMSO-d6):  8.52 (t, J = 5.3 Hz, 1H, NH), 7.87 (d, J = 8.3 Hz, 
2H, Ar), 7.68 (d, J = 8.3 Hz, 2H, Ar), 7.39 (d, J = 7.3 Hz, 2H, Ar), 7.35 (d, J = 7.4 Hz, 2H, 
Ar), 7.24-7.33 (m, 3H, Ar and alkene), 6.84 (d, J = 2.0 Hz, 2H, Ar), 6.46 (t, J = 2.0 Hz, 
1H, Ar), 5.53 (d, J = 4.0Hz, 1H, OH), 4.81 (dd, J = 4.8, 8.3 Hz, 1H, CHOH), 3.79 (s, 6H, 
2 x OCH3), 3.49-3.54 (m, 1H, NHCH2), 3.34-3.37 (m, 1H, NHCH2). 13 C-NMR (DMSO-
d6): 166.0 (C=O), 160.7, 143.8, 139.6, 138.8, 133.3 (C, Ar), 130.7, 128.1, 128.0, 127.7, 
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127.0, 126.2, 126.0, 104.7, 100.2 (CH, Ar), 71.2 (CH, CH-OH), 55.2 (2 x OCH3), 47.7 
(CH2). Anal. Calcd. for C25H25O4N (403.47): C, 74.42 %, H, 6.25 %, N, 3.47 %. Found: 
C, 74.25 %, H, 6.52 %, N, 3.72 %. 
 N-(2-Hydroxy-2-phenylethyl)-4-[(E)-2-(3,4,5-trimethoxyphenyl)vinyl]benzamide 
(6e). A white solid was obtained. Yield: 75 %, Rf 0.61 (petroleum ether – EtOAc 1:3 v/v); 
m.p. 166-168 oC; 1H-NMR (DMSO-d6):  8.50 (t, J = 5.5 Hz, 1H, NH), 7.87 (d, J = 8.2 
Hz, 2H, Ar), 7.66 (d, J = 8.2 Hz, 2H, Ar), 7.24-7.40 (m, 7H, Ar and alkene), 6.97 (s, 2H, 
Ar), 5.34 (bs, 1H, OH), 4.81 (bs, 1H, CHOH), 3.85 (s, 6H, 2 x OCH3), 3.70 (s, 3H, 
OCH3), 3.36-3.53 (m, 2H, NHCH2). 13 C-NMR (DMSO-d6): 166.0 (C=O), 153.06, 
143.8, 139.9, 137.7, 133.1, 132.5 (C, Ar), 130.3, 128.0, 127.8, 127.0, 126.9, 126.0, 104.2, 
(CH, Ar), 71.2 (CH, CH-OH), 60.1 (OCH3), 55.9 (2 x OCH3), 47.7 (CH2). HRMS (EI) 
m/z Calcd for C26H28NO5 (M+H)+ 434.1962. Found 434.1961. 
       N-(2-Hydroxy-2-phenyl-ethyl)-4-phenylsulfamoyl-benzamide (10). A white solid was 
obtained. Yield: 94 %, Rf 0.55 (petroleum ether – EtOAc 1:3 v/v); m.p. 200-202 oC; 1H-
NMR (DMSO-d6):  10.31 (bs, 1H, NHSO2R), 8.73 (t, J = 5.7 Hz, 1H, NH), 7.93 (d, J = 
8.6 Hz, 2H, Ar), 7.82 (d, J = 8.6 Hz, 2H, Ar), 7.32-7.37 (m, 4H, Ar), 7.22-7.26 (m, 3H, 
Ar), 7.09 (m, 2H, Ar), 7.04 (m, 1H, Ar), 5.51 (d, J = 4.3 Hz, 1H, OH), 4.75 (m, 1H, 
CHOH), 3.46 (m, 1H, NHCH2), 3.30 (m, 1H, NHCH2). 13 C-NMR (DMSO-d6): 165.1 
(C=O), 143.5, 141.5, 138.3, 137.4 (C, Ar), 129.1, 128.0, 128.0, 127.0, 126.6, 125.9, 
124.2, 120.2 (CH, Ar), 70.9 (CH, CH-OH), 47.7 (CH2). Anal. Calcd. for C21H20O4N3S 
(396.45): C, 63.62 %, H, 5.08 %, N, 7.06 %. Found: C, 63.45 %, H, 5.11 %, N, 7.16 %. 
 
 General Method -  Synthesis of 4,5-dihydro-1,3-oxazole Derivatives (7 and 11). To 
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a cooled (0 °C ) solution of carboxamide (6 or 10) (3 mmol) in anhydrous THF (20 mL) 
was added methanesulfonyl chloride (24 mmol) and the mixture stirred at 0 °C for 3 h, 
Then triethylamine (36 mmol) was added dropwise and the reaction stirred at room 
temperature overnight. The mixture was quenched by the addition of aqueous ammonia 
solution (28 %, 1 mL). After stirring at room temperature for 15 min the mixture was 
concentrated in vacuo and finally distributed between ethyl acetate (150 mL) and H2O (2 
x 100 mL). After repeated extraction the organic phases were dried and evaporated in 
vacuo. 
  (E)-2-(4-(4-Fluorostyryl)phenyl)-5-phenyl-4,5-dihydrooxazole (7b). A white solid 
was obtained after purification by flash column chromatography (petroleum ether – ethyl 
acetate 100:0 v/v increasing to 70:30 v/v). Yield: 87 %, Rf 0.86 (petroleum ether – EtOAc 
1:3 v/v); m.p. 148-150 oC; 1H-NMR (DMSO-d6):  7.94 (d, J = 8.3 Hz, 2H, Ar), 7.68-
7.72 (m, 4H, Ar), 7.22-7.43 (m, 9H, Ar and alkene), 5.77 (dd, Jx,a = 7.7 Hz, Jx,b = 10.2 Hz, 
1H, CHx), 4.45 (dd, Jb,x = 10.2 Hz, Jb,a = 14.7 Hz, 1H, CHb), 3.85 (dd, Ja,x = 7.7 Hz, Ja,b = 
14.7 Hz, 1H, CHa). 13C-NMR (DMSO-d6):  162.8, 162.2, 160.9, 141.3, 140.1, 133.3, 
126.1 (C), 129.2, 128.7, 128.7, 128.6, 128.2, 128.1, 127.4. 126.6, 125.6, 115.7, 115.6 
(CH), 80.1 (CH, oxazole), 62.6 (CH2 oxazole). Anal. Calcd. for C23H18NOF•0.2H2O  
(347.00): C, 79.61 %, H, 5.34 %, N, 4.04 %. Found: C, 79.51 %, H, 5.43 %, N, 3.75 %. 
  (E)-2-(4-(4-Methoxystyryl)phenyl)-5-phenyl-4,5-dihydrooxazole (7c). A pale 
yellow solid was obtained after purification by flash column chromatography (petroleum 
ether – ethyl acetate 100:0 v/v increasing to 80:20 v/v). Yield: 42 %, Rf 0.77 (petroleum 
ether – EtOAc 1:3 v/v); m.p. 160-162 oC; 1H-NMR (DMSO-d6):  7.92 (d, J = 8.3 Hz, 
2H, Ar), 7.68 (d, J = 8.3 Hz, 2H, Ar), 7.59 (d, J = 8.8 Hz, 2H, Ar), 7.32-7.43 (m, 5H, Ar), 
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7.16 (d, J = 16.7 Hz, 1H, alkene), 7.17 (d, J = 16.6 Hz, 1H, alkene), 6.97 (d, J = 8.8 Hz, 
2H, Ar), 5.80 (dd, Jx,a = 7.6 Hz, Jx,b = 10.1 Hz, 1H, CHx), 4.45 (dd, Jb,x = 10.1 Hz, Jb,a = 
14.9 Hz, 1H, CHb), 3.84 (dd, Ja,x = 7.5 Hz, Ja,b = 14.9 Hz, 1H, CHa), 3.79 (s, 3H, OCH3). 
13C-NMR (DMSO-d6):  162.3, 159.3, 141.3, 140.6, 129.3, 125.6 (C), 130.1, 128.7, 
128.2, 128.1, 128.1, 125.6, 125.1, 114.2, 113.8 (CH), 80.0 (CH, oxazole), 62.6 (CH2 
oxazole), 55.2 (OCH3). Anal. Calcd. for C24H21NO2 (355.43): C, 81.10 %, H, 5.95 %, N, 
3.94 %. Found: C, 81.14 %, H, 6.30 %, N, 3.75 %. 
 (E)-2-(4-(3,5-Dimethoxystyryl)phenyl)-5-phenyl-4,5-dihydrooxazole (7d). A yellow 
oil was obtained after purification by flash column chromatography (petroleum ether – 
ethyl acetate 100:0 v/v increasing to 70:30 v/v). Yield: 77 %, Rf 0.60 (petroleum ether – 
EtOAc 1:3 v/v); 1H-NMR (CDCl3):  8.03 (d, J = 8.4 Hz, 2H, Ar), 7.59 (d, J = 8.4 Hz, 
2H, Ar), 7.36-7.43 (m, 5H, Ar), 7.16 (d, J = 16.4 Hz, 1H, alkene), 7.12 (d, J = 16.4 Hz, 
1H, alkene), 6.71 (d, J = 2.2 Hz, 2H, Ar), 6.45 (t, J = 2.2 Hz, 1H, Ar), 5.69 (dd, Jx,a = 8.1 
Hz, Jx,b = 10.2 Hz, 1H, CHx), 4.51 (dd, Jb,x = 10.2 Hz, Jb,a = 14.7 Hz, 1H, CHb), 4.03 (dd, 
Ja,x = 8.0 Hz, Ja,b = 14.7 Hz, 1H, CHa), 3.86 (s, 6H, 2 x OCH3). 13C-NMR (CDCl3):  
163.9, 161.1, 141.0, 140.3, 138.9, 126.6 (C), 130.5, 128.8, 128.7, 128.3, 128.3, 126.5, 
125.8, 104.8, 100.5 (CH), 81.1 (CH, oxazole), 63.2 (CH2 oxazole), 55.4 (2 x OCH3). 
HRMS (EI) m/z Calcd for C25H24NO3 (M+H)+ 386.1751. Found 381.1753. 
 (E)-2-(4-(3,4,5-Trimethoxystyryl)phenyl)-5-phenyl-4,5-dihydrooxazole (7e). A 
yellow solid was obtained after purification by flash column chromatography (petroleum 
ether – ethyl acetate 100:0 v/v increasing to 70:30 v/v). Yield: 55 %, Rf 0.75 (petroleum 
ether – EtOAc 1:3 v/v); m.p. 120-122 oC; 1H-NMR (CDCl3):  8.03 (d, J = 8.3 Hz, 2H, 
Ar), 7.59 (d, J = 8.3 Hz, 2H, Ar), 7.36-7.43 (m, 5H, Ar), 7.16 (d, J = 16.2 Hz, 1H, 
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alkene), 7.06 (d, J = 16.2 Hz, 1H, alkene), 6.78 (s, 2H, Ar), 5.69 (dd, Jx,a = 8.0 Hz, Jx,b = 
10.1 Hz, 1H, CHx), 4.51 (dd, Jb,x = 10.1 Hz, Jb,a = 14.9 Hz, 1H, CHb), 4.03 (dd, Ja,x = 8.0 
Hz, Ja,b = 14.9 Hz, 1H, CHa), 3.97 (s, 3H, OCH3), 3.94 (s, 6H, 2 x OCH3). 13C-NMR 
(CDCl3):  163.8, 153.5, 141.1, 140.3, 138.4, 132.6, 126.5 (C), 130.5, 128.8, 128.7, 
128.3, 127.3, 126.3, 125.8, 103.9 (CH), 81.1 (CH, oxazole), 63.2 (CH2 oxazole), 61.0 
(OCH3), 56.2 (2 x OCH3). Anal. Calcd. for C26H35NO4•0.1H2O  (417.29): C, 74.84 %, H, 
6.04 %, N, 3.36 %. Found: C, 74.53 %, H, 6.01 %, N, 3.41 %. 
     N-Methanesulfonyl-N-phenyl-4-(5-phenyl-4,5-dihydro-oxazol-2-yl)-benzene 
sulfonamide (11). A white solid was obtained after purification by flash column 
chromatography (petroleum ether – ethyl acetate 100:0 v/v increasing to 50:50 v/v). 
Yield: 55 %, Rf 0.56 (petroleum ether – EtOAc 1:1 v/v); m.p. 148-150 oC; 1H-NMR 
(DMSO-d6):  8.18 (d, J = 8.5 Hz, 2H, Ar), 7.96 (d, J = 8.5 Hz, 2H, Ar), 7.50 (t, J = 7.5 
Hz, 1H, Ar), 7.43-7.47 (m, 4H, Ar), 7.38-7.40 (m, 3H, Ar), 7.18 (d, J = 7.6 Hz, 2H, Ar), 
5.74 (dd, Jx,a = 8.2 Hz, Jx,b = 10.3 Hz, 1H, CHx), 4.55 (dd, Jb,x = 10.3 Hz, Jb,a = 15.3 Hz, 
1H, CHb), 4.08 (dd, Ja,x = 8.2 Hz, Ja,b = 15.3 Hz, 1H, CHa HCH2), 3.55 (s, 3H, -SO2CH3). 
13 C-NMR (DMSO-d6): 162.4, 140.6, 140.3, 133.6, 132.9 (C, Ar), 131.1, 130.5, 129.5, 
128.9, 128.7, 128.6, 125.7 (CH, Ar), 81.7 (CH, CH-OH), 63.3 (CH2), 43.9 (CH3). Anal. 
Calcd. for C22H20O5N2S2 •0.1H2O (457.88): C, 57.27 %, H, 4.44 %, N, 6.11 %. Found: C, 
57.23 %, H, 4.62 %, N, 6.13. 
General Method - synthesis of Imidazole Derivatives (8 and 12). A mixture of oxazole (7 
or 11) (1 mmol) and imidazole (40 mmol) dissolved in isopropyl acetate (5 mL) was 
heated at 125 °C for 48 h. After completion of the reaction the mixture was partitioned 
between water (100 mL) and ethyl acetate (150 mL). The organic layer was washed three 
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times with water (3 x 100 mL), dried over MgSO4 and concentrated in vacuo.  
 (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-4-(4-fluorostyryl)benzamide (8b). 
Purification by flash column chromatography (CH2Cl2 – MeOH 97:3 v/v) gave a pale 
yellow solid. Yield: 74 %, Rf 0.60 (CH2Cl2 – MeOH 9:1 v/v); m.p. 192-194 oC; 1H-NMR 
(DMSO-d6):  8.69 (t, J = 5.3 Hz 1H, NH), 7.84 (s, 1H, imid), 7.76 (d, J = 8.3 Hz, 2H, 
Ar), 7.65-7.69 (m, 5H, Ar and imid), 7.33-7.39 (m, 6H, Ar), 7.21-7.26 (m, 3H, Ar), 6.91 
(s, 1H, imid), 5.66 (dd, Jx,b = 6.0 Hz, Jx,a = 9.3 Hz, 1H, CHx), 4.03-4.10 (m, 1H, CHb), 
3.94-3.99 (m, 1H, CHa). 13C-NMR (DMSO-d6): 166.3 (C=O), 162.8, 160.9, 139.9, 
139.3, 133.3, 132.8 (C), 136.8, 129.1, 128.7, 128.6, 128.6, 128.1, 128.1, 127.6, 127.4, 
126.8, 126.2, 118.3, 115.7, 115.5 (CH), 59.4 (CH), 43.5 (CH2). Anal. Calcd. for 
C26H22N3OF•0.3H2O (416.88): C, 74.90 %, H, 5.46 %, N, 10.08 %. Found: C, 74.79 %, 
H, 5.48 %, N, 10.40 %. 
 (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-4-(4-methoxystyryl)benzamide (8c). 
Purification by flash column chromatography (CH2Cl2 – MeOH 97:3 v/v) gave a white 
solid. Yield: 30 %, Rf 0.66 (CH2Cl2 – MeOH 9:1 v/v); m.p. 188-190 oC; 1H-NMR 
(DMSO-d6):  8.69 (t, J = 5.3 Hz 1H, NH), 7.85 (s, 1H, imid), 7.74 (d, J = 8.4 Hz, 2H, 
Ar), 7.62 (d, J = 8.4 Hz, 2H, Ar), 7.52 (d, J = 8.6 Hz, 2H, Ar),  7.38 (m, 5H, Ar and imid), 
7.28-7.33 (m, 2H, Ar and alkene), 7.13 (d, J = 16.6 Hz, 1H, alkene), 6.96 (d, J = 8.6 Hz, 
2H, Ar), 6.92 (s, 1H, imid), 5.68 (dd, Jx,b = 5.7 Hz, Jx,a = 9.1 Hz, 1H, CHx), 4.03-4.10 (m, 
1H, CHb), 3.94-3.99 (m, 1H, CHa), 3.78 (s, 3H, OCH3). 13C-NMR (DMSO-d6): 166.3 
(C=O), 159.3, 140.4, 139.3, 132.3, 129.3 (C), 130.0, 129.9, 128.7, 128.4, 128.3, 128.1, 
127.6, 126.8, 125.9, 125.1, 114.2, 113.8 (CH), 59.5 (OCH3), 55.2 (CH), 43.4 (CH2). 
HRMS (EI) m/z Calcd for C27H26N3O2 (M+H)+ 424.2020. Found 424.2021. 
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 (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-4-(3,5-dimethoxystyryl)benzamide (8d). 
Purification by flash column chromatography (CH2Cl2 – MeOH 97:3 v/v) gave a white 
solid. Yield: 62 %, Rf 0.46 (CH2Cl2 – MeOH 9:1 v/v); m.p. 210-212 oC; 1H-NMR 
(DMSO-d6):  8.73 (t, J = 5.5 Hz 1H, NH), 7.84 (s, 1H, imid), 7.72 (d, J = 8.4 Hz, 2H, 
Ar), 7.66 (d, J = 8.4 Hz, 2H, Ar), 7.38-7.40 (m, 5H, Ar and imid), 7.27-7.35 (m, 5H, Ar 
and alkene), 6.91 (s, 1H, imid), 6.81 (d, J = 2.0 Hz, 2H, Ar), 6.45 (t, J = 2.0 Hz, 1H, Ar), 
5.68 (dd, Jx,b = 5.7 Hz, Jx,a = 9.4 Hz, 1H, CHx), 4.05-4.11 (m, 1H, CHb), 3.95-4.00 (m, 
1H, CHa), 3.79 (s, 6H, 2 x OCH3). 13C-NMR (DMSO-d6): 166.3 (C=O), 160.7, 139.9, 
139.3, 138.7, 132.8 (C), 136.8, 130.2, 128.7, 128.5, 128.1, 128.0, 127.6, 126.8, 126.3, 
118.3, 104.7, 100.3 (CH), 59.4 (2 x OCH3), 55.2 (CH), 43.4 (CH2). Anal. Calcd. for 
C28H27N3O3•0.1H2O (455.34): C, 73.86 %, H, 5.98 %, N, 9.23 %. Found: C, 73.61 %, H, 
5.61 %, N, 9.18 %. 
 (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-4-(3,4,5-trimethoxystyryl)benzamide 
(8e). Purification by flash column chromatography (CH2Cl2 – MeOH 96:4 v/v) gave a 
white solid. Yield: 71 %, Rf 0.48 (CH2Cl2 – MeOH 9:1 v/v); m.p. 96-98 oC; 1H-NMR 
(DMSO-d6):  8.72 (t, J = 5.4 Hz 1H, NH), 7.84 (s, 1H, imid), 7.77 (d, J = 8.3 Hz, 2H, 
Ar), 7.65 (d, J = 8.3 Hz, 2H, Ar), 7.28-7.39 (m, 8H, Ar and imid and alkene), 6.96 (s, 2H, 
Ar), 6.91 (s, 1H, imid), 5.68 (dd, Jx,b = 5.8 Hz, Jx,a = 9.4 Hz, 1H, CHx), 4.05-4.11 (m, 1H, 
CHb), 3.95-4.00 (m, 1H, CHa), 3.96 (s, 3H, OCH3), 3.84 (s, 6H, 2 x OCH3). 13C-NMR 
(DMSO-d6): 166.3 (C=O), 153.1, 140.1, 139.3, 137.7, 132.6, 132.4 (C), 136.8, 130.5, 
128.7, 128.5, 128.1, 127.7, 126.8, 126.8, 126.0, 118.3, 104.2 (CH), 60.1 (OCH3), 55.4 (2 
x OCH3), 55.9 (CH), 43.5 (CH2). Anal. Calcd. for C29H29N3O4•0.3H2O (488.97): C, 71.24 
%, H, 6.10 %, N, 8.59 %. Found: C, 70.95 %, H, 5.78 %, N, 8.64 %.  
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    N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-4-phenyl sulfonyl-benzamide (12). Purification 
by flash column chromatography (CH2Cl2 – MeOH 90:10 v/v) gave a white solid. Yield: 
18 %, Rf 0.74 (CH2Cl2 – MeOH 9:1 v/v); m.p. 178-180 oC; 1H-NMR (DMSO-d6):  10.35 
(bs, 1H, NHSO2R), 8.90 (t, J = 5.5 Hz, 1H, NH), 7.78-7.85 (m, 5H, Ar and imid), 7.30-
7.41 (m, 4H, Ar), 7.33 (m, 2H, Ar), 7.20-7.34 (m, 2H, Ar),7.06-7.09 (m, 2H, Ar and 
imid), 7.03 (m, 1H, Ar), 6.90 (s, 1H, imid), 5.62 (dd, Jx,b = 5.7 Hz, Jx,a = 9.5 Hz, 1H, 
CHx), 4.02-4.10 (m, 1H, CHb), 3.93-4.00 (m, 1H, CHa),. 13 C-NMR (DMSO-d6): 165.6 
(C=O), 141.7, 139.1, 137.9, 137.3 (C, Ar), 129.1, 128.7, 128.5, 128.0, 126.8, 126.7, 
124.3, 120.2, 118.2 (CH), 59.3 (CH), 43.4 (CH2). HRMS (EI) m/z Calcd for C24H23O3N4 
(M+H)+ 447.1485, Found 447.1476. 
Synthesis of 4-[2-(4-Fluoro-phenyl)-ethyl]-N-(2-imidazol-1-yl-2-phenyl-ethyl)-benzamide 
(8f). Pd/C catalyst 10% (0.17 g) was added to a solution of compound 8f (0.2 g, 0.4 
mmol) in THF (20 mL) and the reaction was stirred under a H2 atmosphere for 72 h.  
After that time the mixture was filtered through celite. The solvent was removed under 
reduced pressure and the oil formed was purified by flash column chromatography 
(CH2Cl2 - MeOH 100:0 v/v increasing to 98:2 v/v) to give the pure product as white 
solid. Yield: 52% Rf 0.60 (CH2Cl2 – MeOH 9:1 v/v); m.p. 130-132 oC; 1H-NMR (DMSO-
d6):  8.63 (t, J = 5.5 Hz 1H, NH), 7.83 (s, 1H, imid), 7.65 (d, J = 8.2 Hz, 2H, Ar), 7.38 
(m, 4H, Ar), 7.32 (m, 2H, Ar), 7.27 (d, J = 8.2 Hz, 2H, Ar), 7.23 (m, 2H, Ar and imid), 
7.08 (m, 2H, Ar), 6.90 (s, 1H, imid), 5.66 (dd, Jx,b = 5.7 Hz, Jx,a = 9.7 Hz, 1H, CHx), 4.04 
(m, 1H, CHb), 3.95 (m, 1H, CHa), 2.84-2.94 (m, 4H, 2 x CH2). 13C-NMR (DMSO-d6): 
166.5 (C=O), 161.5, 159.6, 144.92, 139.3, 137.27, 131.7 (C), 136.7, 130.1, 130.0, 
128.6, 128.4, 128.2, 128.0, 127.1, 126.8, 126.2, 118.3, 114.9, 114.7 (CH), 59.4 (CH), 43.4 
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(CH2), 36.7 (CH2), 35.65 (CH2). Anal. Calcd. for C26H24N3OF•0.3H2O (418.59): C, 74.60 
%, H, 5.92 %, N, 10.03 %. Found: C, 74.26 %, H, 6.22 %, N, 10.00 %.   
Synthesis of1-(4-bromophenyl)-4,4-dimethylpentan-3-one (15). 1-Bromo-4-
(bromomethyl)benzene (13) (1.95 g, 7.8 mmol) was added to a solution of indium (III) 
bromide (0.14 g, 0.4 mmol) and 1-(tert-butylvinyloxy)trimethylsilane (14) (2.7 mL, 12.5 
mmol) in CH2Cl2 (4 mL). The mixture was stirred for 2 h at room temperature and then 
poured into aqueous saturated NaHCO3 (100 mL). The resulting mixture was extracted 
with Et2O (100 mL), the organic layer dried over MgSO4 and the solvent removed under 
reduced pressure. Purification by flash column chromatography (petroleum ether - EtOAc 
100/0 v/v increasing to 95:5 v/v) gave a yellow oil. Yield: 62 %, Rf 0.74 (petroleum ether 
– EtOAc 9:1 v/v); 1H-NMR (CDCl3),: δ 7.40 (d, J = 8.4 Hz, 2H, Ar), 7.08 (d, J =  8.4 Hz, 
2H, Ar), 2.84 (m, 2H, CH2), 2.78 (m, 2H, CH2), 1.11 (s, 9H, 3 x CH3).13C-NMR (CDCl3), 
: δ 214.50, 140.57, 119.75, (C), 131.45, 130.21 (4 x CH), 44.05 (C, tBu), 38.11 (CH2),  
29.40 (CH2),  26.29 (CH3 tBu). HRMS (EI) m/z Calcd for C13H18OBr (M+H)+ 269.0536, 
Found 269.0537. 
 
General Method – Synthesis of Ketones (16). Vinyl benzene (2) (4.5 mmol), 1-(4-
bromophenyl)-4,4-dimethylpentan-3-one (15) (4.5 mmol) and triethylamine (9 mmol) 
were heated in the presence of tri(o-tolylphosphine) (TOP, 0.16 mmol) and palladium (II) 
acetate (0.03 mmol) in a sealed tube at 110 oC for 6h. After the reaction was complete, 
water was added (10 mL). The product was partitioned between diethyl ether (100 mL) 
and water (100 mL), the organic layer dried (MgSO4) and concentrated under reduced 
pressure.  
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 4,4-Dimethyl-1-(4-styrylphenyl)pentan-3-one (16a). Purification by flash column 
chromatography (petroleum ether – EtOAc 95:5 v/v) gave a pale yellow solid. Yield: 78 
%, Rf 0.57 (petroleum ether – EtOAc 9:1 v/v); m.p. 70-72 oC; 1H-NMR (CDCl3):  7.53 
(d, J = 8.0 Hz 2H, Ar), 7.46 (d, J = 8.1 Hz, 2H, Ar), 7.37 (m, 2H, Ar), 7.28 (m, 1H, Ar), 
7.21 (d, J = 7.2 Hz, 2H, Ar), 7.12 (d, J = 16.4 Hz, 1H, alkene), 7.08 (d, J = 16.4 Hz, 1H, 
alkene), 2.92 (m, 2H, CH2), 2.83 (m, 2H, CH2), 1.14 (s, 9H, tBu). 13C-NMR (CDCl3): 
214.8 (C=O), 141.2, 137.5, 135.2 (C), 128.8, 128.5, 128.3, 128.3, 128.1, 128.0, 126.6 
(11 x CH), 44.1 (C, tBu), 38.3 (CH2), 29.9 (CH2), 26.3 (CH3, tBu). HRMS (EI) m/z Calcd 
for C21H25O (M+H)+ 293.1900. Found 293.1901. 
 1-(4-(3,5-Dimethoxystyryl)phenyl)-4,4-dimethylpentan-3-one (16b). Purification by 
flash column chromatography (petroleum ether – EtOAc 95:5 v/v) gave a pale yellow 
solid. Yield: 74 %, Rf 0.57 (petroleum ether – EtOAc 9:1 v/v); m.p. 60-62 oC; 1H-NMR 
(CDCl3):  7.45 (d, J = 8.2 Hz 2H, Ar), 7.20 (d, J = 8.2 Hz, 2H, Ar), 7.08 (d, J = 16.1 Hz, 
1H, alkene), 7.02 (d, J = 16.4 Hz, 1H, alkene), 6.69 (d, J = 2.2 Hz, 2H, Ar), 6.42 (t, J = 
2.2 Hz, 1H, Ar), 3.85 (s, 6H, 2 x OCH3), 2.90 (m, 2H, CH2), 2.83 (m, 2H, CH2), 1.14 (s, 
9H, tBu). 13C-NMR (CDCl3): 214.8 (C=O), 161.0, 141.5, 139.5, 135.0 (5 x C), 129.0, 
128.9, 128.1, 126.7, 104.5, 99.9 (9 x CH), 55.4 (2 x OCH3), 44.1 (C, tBu), 38.3 (CH2), 
29.9 (CH2), 26.3 (CH3, tBu). HRMS (EI) m/z Calcd for C23H29O3 (M+H)+ 353.2111. 
Found 353.2114. 
General Method – Synthesis of Alcohols (17). To a cooled solution (0 oC) of ketone (16) 
(3.4 mmol) in ethanol (60 mL) was added NaBH4 (4.1 mmol) and the reaction stirred at 
room temperature for 2h. The reaction was concentrated under reduced pressure then 1M 
aqueous HCl (50 mL) added to the residue. The resulting white oil was extracted with 
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diethyl ether (2 x 50 mL) and the organic layer back-extracted with water (2 x 25 mL), 
dried (MgSO4) and concentrated to give the pure compound.  
 4,4-Dimethyl-1-(4-styrylphenyl)pentan-3-ol (17a). Obtained as a white solid. Yield: 
67 %, Rf 0.41 (petroleum ether – EtOAc 9:1 v/v); m.p. 76-78 oC; 1H-NMR (CDCl3):  
7.53 (d, J = 7.3 Hz 2H, Ar), 7.47 (d, J = 8.1 Hz, 2H, Ar), 7.37 (m, 2H, Ar), 7.28 (m, 1H, 
Ar), 7.24 (d, J = 7.9 Hz, 2H, Ar), 7.13 (d, J = 16.2 Hz, 1H, alkene), 7.09 (d, J = 16.2 Hz, 
1H, alkene), 3.26 (m, 1H, CHOH), 2.95 (m, 1H, CH2), 2.67 (m, 1H, CH2), 1.88 (m, 1H, 
CH2), 1.62 (m, 1H, CH2), 1.43 (d, J = 5.4 Hz, 1H, OH), 0.92 (s, 9H, tBu). 13C-NMR 
(CDCl3): 142.1, 137.5, 135.0 (C), 128.9, 128.7, 128.6, 127.9, 127.5, 126.6, 126.4 (11 x 
CH), 79.3 (CHOH), 35.1 (C, tBu), 33.3 (CH2), 33.1 (CH2), 25.7 (CH3, tBu). HRMS (EI) 
m/z Calcd for C21H27O (M+H)+ 295.2056. Found 295.2062. 
1-(4-(3,5-Dimethoxystyryl)phenyl)-4,4-dimethylpentan-3-ol (17b). Obtained as a clear 
thick syrup. Yield: 83 %, Rf 0.41 (petroleum ether – EtOAc 9:1 v/v); 1H-NMR (CDCl3):  
7.47 (d, J = 8.2 Hz 2H, Ar), 7.25 (d, J = 8.2 Hz, 2H, Ar), 7.10 (d, J = 16.3 Hz, 1H, 
alkene), 7.03 (d, J = 16.3 Hz, 1H, alkene), 6.70 (d, J = 2.2 Hz, 2H, Ar), 6.43 (t, J = 2.2 
Hz, 1H, Ar), 3.86 (s, 6H, 2 x OCH3), 3.26 (d, J = 10.5 Hz, 1H, CHOH), 2.96 (m, 1H, 
CH2), 2.67 (m, 1H, CH2), 1.89 (m, 1H, CH2), 1.63 (m, 1H, CH2), 1.55 (bs, 1H, OH), 0.94 
(s, 9H, tBu). 13C-NMR (CDCl3): 161.0, 142.3, 139.6, 134.8 (C), 129.2, 128.9, 128.2, 
126.7, 104.5, 99.9 (9 x CH), 79.3 (CHOH), 55.4 (2 x OCH3), 35.0 (C, tBu), 33.3 (CH2), 
33.1 (CH2), 25.7 (CH3, tBu). HRMS (EI) m/z Calcd for C23H31O3 (M+H)+ 355.2268. 
Found 355.2258. 
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Synthesis of 1-(4-(3,5-Dimethoxystyryl)phenyl)-4,4-dimethylpentan-3-yl-1H-imidazole-1-
carboxylate (18b). To a solution of alcohol 17b (0.5 g, 1.4 mmol) in dry CH3CN (20 mL) 
was added imidazole (0.3 g, 4.2 mmol) and 1,1’-carbonyldiimidazole (0.34 g, 2.1 mmol). 
The mixture was heated at 70 oC for 48 h. After cooling the reaction was extracted 
between CH2Cl2 (50 mL) and H2O (50 mL), the aqueous layer was further washed with 
CH2Cl2 (2 x 50 mL), then the combined organic layers washed with and H2O (3 x 50 
mL), dried (MgSO4) and concentrated under reduced pressure. Purification by flash 
column chromatography (petroleum ether – EtOAc 9:1 v/v increasing to 3:2 v/v) gave a 
thick colourless oil. Yield: 65 %, Rf 0.33 (petroleum ether – EtOAc 7:3 v/v); 1H-NMR 
(CDCl3):  8.17 (s, 1H, imid), 7.46 (m, 3H, Ar + imid), 7.25 (d, J = 8.2 Hz, 2H, Ar), 7.12 
(s, 1H, imid), 7.03 (d, J = 16.2 Hz, 1H, alkene), 6.97 (d, J = 16.2 Hz, 1H, alkene), 6.69 (d, 
J = 2.2 Hz, 2H, Ar), 6.39 (t, J = 2.2 Hz, 1H, Ar), 4.95 (dd, J = 3.0, 9.6 Hz, 1H, 
CHOC(O)imid), 3.86 (s, 6H, 2 x OCH3), 2.69 (m, 2H, CH2), 2.05 (m, 2H, CH2), 0.94 (s, 
9H, tBu). 13C-NMR (CDCl3): 161.0, 149.0, 140.6, 139.4, 135.2 (6 x C), 137.0, 130.6, 
128.6, 128.3, 128.2, 126.7, 117.1, 104.6, 99.9 (12 x CH), 86.3 (CHOC(O)imid), 55.4 (2 x 
OCH3), 32.5 (C, tBu), 35.1 (CH2), 33.4 (CH2), 25.8 (CH3, tBu). HRMS (EI) m/z Calcd 
for C27H33N2O4 (M+H)+ 449.2435. Found 449.2431. 
 
General Method – Synthesis of Sulfonates (20 and 21). To a cooled solution (0 oC) of 
alcohol (17) (1.8 mmol) and 4-dimethylaminopyridine (0.4 mmol) in dry CH2Cl2 (7 mL) 
and pyridine (0.7 mL) was added methane sulfonyl chloride or toluene sulfonyl chloride 
(4 mmol) dropwise.  The reaction was stirred at 0 oC for 10 min then at room temperature 
for 24h (mesyl derivative) or reflux for 24 h (tosyl derivative). On completion and 
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cooling to room temperature (tosyl reaction), the crude reaction mixture was washed with 
saturated aqueous NaHCO3 (30 mL) and the organic layer separated. The aqueous layer 
was back extracted with CH2Cl2 (30 mL), then the combined organic layers washed with 
aqueous 1M HCl (30 mL) and saturated aqueous NaHCO3 (30 mL), dried (MgSO4) and 
concentrated under reduced pressure.  
 4,4-Dimethyl-1-(4-styrylphenyl)pentan-3-yl methanesulfonate (20a). Purification by 
flash column chromatography (petroleum ether – EtOAc 9:1 v/v) gave a white solid. 
Yield: 52 %, Rf 0.53 (petroleum ether – EtOAc 4:1 v/v); m.p. 80-82 oC; 1H-NMR 
(CDCl3):  7.53 (d, J = 7.6 Hz 2H, Ar), 7.48 (d, J = 8.0 Hz, 2H, Ar), 7.38 (m, 2H, Ar), 
7.28 (m, 1H, Ar), 7.24 (d, J = 8.0 Hz, 2H, Ar), 7.12 (d, J = 16.6 Hz, 1H, alkene), 7.09 (d, 
J = 16.6 Hz, 1H, alkene), 4.58 (t, J = 5.6 Hz, 1H, CHOMs), 3.11 (s, 3H, Ms), 2.97 (m, 
1H, CH2), 2.73 (m, 1H, CH2), 1.99 (m, 2H, CH2), 1.01 (s, 9H, tBu). 13C-NMR (CDCl3): 
141.0, 137.5, 135.3 (C), 128.7, 128.5, 128.2, 127.5, 126.7, 126.6, 126.4 (11 x CH), 91.5 
(CHOMs), 38.9 (CH3, Ms), 35.3 (C, tBu), 32.8 (CH2), 32.7 (CH2), 26.2 (CH3, tBu). 
HRMS (EI) m/z Calcd for C22H32NO3S (M+NH4)+ 390.2097. Found 390.2094.. 
 1-(4-(3,5-Dimethoxystyryl)phenyl)-4,4-dimethylpentan-3-yl methanesulfonate 
(20b). Purification by flash column chromatography (petroleum ether – EtOAc 9:1 v/v) 
gave a yellow oil. Yield: 84 %, Rf 0.53 (petroleum ether – EtOAc 4:1 v/v); 1H-NMR 
(CDCl3):  7.46 (d, J = 8.2 Hz 2H, Ar), 7.24 (d, J = 8.1 Hz, 2H, Ar), 7.09 (d, J = 16.3 Hz, 
1H, alkene), 7.02 (d, J = 16.3 Hz, 1H, alkene), 6.69 (d, J = 2.2 Hz, 2H, Ar), 6.42 (t, J = 
2.2 Hz, 1H, Ar), 4.57 (dd, J = 3.1, 5.0 Hz, 1H, CHOMs), 3.85 (s, 6H, 2 x OCH3), 3.10 (s, 
3H, Ms), 2.97 (m, 1H, CH2), 2.73 (m, 1H, CH2), 1.98 (m, 2H, CH2), 1.00 (s, 9H, tBu). 
13C-NMR (CDCl3): 161.0, 141.1, 139.5, 135.1 (5 x C), 128.9, 128.8, 128.1, 126.7, 
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104.5, 99.9 (9 x CH), 91.5 (CHOMs), 55.4 (2 x OCH3), 38.9 (CH3, Ms), 35.0 (C, tBu), 
32.8 (CH2), 32.7 (CH2), 26.2 (CH3, tBu). HRMS (EI) m/z Calcd for C24H33SO5 (M+H)+ 
433.2043. Found 433.2043. 
 1-(4-(3,5-Dimethoxystyryl)phenyl)-4,4-dimethylpentan-3-yl toluenesulfonate 
(21b). Purification by flash column chromatography (petroleum ether – EtOAc 9:1 v/v) 
gave a thick colourless oil. Yield: 8 %, Rf 0.37 (petroleum ether – EtOAc 4:1 v/v); 1H-
NMR (CDCl3):  7.86 (d, J = 8.2 Hz 2H, Ar), 7.44 (d, J = 8.0 Hz 2H, Ar), 7.36 (d, J = 8.0 
Hz 2H, Ar), 7.12 (d, J = 8.1 Hz, 2H, Ar), 7.08 (d, J = 16.3 Hz, 1H, alkene), 7.01 (d, J = 
16.3 Hz, 1H, alkene), 6.69 (d, J = 2.2 Hz, 2H, Ar), 6.42 (t, J = 2.1 Hz, 1H, Ar), 4.54 (dd, J 
= 3.1, 5.0 Hz, 1H, CHOTs), 3.85 (s, 6H, 2 x OCH3), 2.75 (m, 1H, CH2), 2.61 (m, 1H, 
CH2), 2.47 (s, 3H, Ts), 1.93 (m, 2H, CH2), 0.91 (s, 9H, tBu). 13C-NMR (CDCl3): 161.0, 
144.2, 141.3, 139.5, 135.4, 135.0 (7 x C), 129.6, 129.0, 128.8, 128.1, 127.5, 126.7, 104.5, 
99.9 (13 x CH), 92.2 (CHOTs), 55.4 (2 x OCH3), 35.4 (C, tBu), 32.9 (CH2), 32.8 (CH2), 
26.2 (CH3, tBu), 21.6 (CH3, Ts). HRMS (EI) m/z Calcd for C30H37SO5 (M+H)+ 509.2356. 
Found 509.2350. 
 
Synthesis of 2-Imidazol-1-yl-4,4-dimethyl-1-(4-styryl-phenyl)-pent-1-en-3-one (24). To a 
stirred solution of 22 (0.48 g, 2.8 mmol) and K2CO3 (0.48 g, 3.5 mmol) in Ac2O (8 mL) 
was added 23 (0.72 g, 3.5 mmol). The mixture was stirred for 3 h at room temperature. 
After quenched with water (50 mL), the resulting mixture was extracted with EtOAc (50 
mL × 4). The combined organic layer was washed with brine (150 mL), dried over 
MgSO4, and concentrated in vacuo. The residual oil was purified by silica gel flash 
column chromatography (petroleum ether-EtOAc 100:0 v/v increasing to 50:50 v/v) to 
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obtain the E/Z mixture compound as a yellow solid. Yield: 16 %, Rf 0.65 (petroleum ether 
– EtOAc 1:1 v/v); m.p. 122-124 oC; 1H-NMR (CDCl3): 7.52 (d, J= 7.4 Hz, 2H, Ar), 
7.47 (s, 1H, imid), 7.44 (s, 1H, alkene), 7.36-7.42 (m, 4H, Ar and imid), 7.30 (m, 2H, Ar), 
7.15 (d, J = 16.4 Hz, 1H, alkene), 7.04 (d, J = 16.4 Hz, 1H, alkene), 6.94 (s, 1H, imid), 
6.77 (d, J = 8.4 Hz, 2H, Ar), 1.25 (s, 9H, tBu). 13C-NMR (CDCl3):  203.0 (C=O), 139.7, 
136.7, 132.1, 130.6 (5 C), 137.3, 136.4, 130.8, 130.4, 130.3, 128.7, 128.2, 127.37, 126.9, 
126.7, 119.7 (CH), 44.1 (C, tBu) 27.8 (CH3, tBu). Anal. Calcd. for C24H24N2O•0.1H2O 
(357.99): C, 80.52 %, H, 6.81 %, N, 7.82 %. Found: C, 80.39 %, H, 6.83 %, N, 7.82 %.  
Synthesis of 2-Imidazol-1-yl-4,4-dimethyl-1-(4phenylethyl)-pentan-3-one (25). Reduction 
of (24) by catalytic reduction following the procedure reported for 8f. Purification by 
flash column chromatography (100:0 v/v increasing to 50:50 v/v) gave a white wax. 
Yield: 40 %, Rf  0.21 (petroleum ether – EtOAc 1:1 v/v); 1H-NMR (CDCl3): 7.42 (s, 
1H, imid), 7.24-7.31 (m, 2H, Ar and imid), 7.20 (m, 1H, Ar), 7.14 (m, 2H, Ar), 7.30 (m, 
2H, Ar), 7.03-7.07 (m, 4H, Ar), 6.87-6.91 (m, 2H, Ar and imid), 5.25 (dd, Jx,b = 6.8 Hz, 
Jx,a = 8.4 Hz, 1H, CHx), 3.24 (m, 1H, CHb), 3.09 (m, 1H, CHa), 2.89 (s, 4H, 2 x CH2),  
1.04 (s, 9H, tBu). 13C-NMR (CDCl3):  209.6 (C=O), 141.4, 140.8, 133.3 (4 C), 136.5, 
129.6, 128.9, 128.9, 128.4, 128.3, 125.9, 117.7 (CH), 60.0 (CH), 44.8 (C, tBu), 39.8, 
37.7, 37.3 (CH2), 25.6 (CH3, tBu). HRMS (EI) m/z Calcd for C24H29N2O (M+H)+ 
361.2274. Found 361.2269. 
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